Further improvement of the parent compound SF-1-066 led to BP-5-087 (Figure 3m), a highly potent and selective STAT3 SH2 domain inhibitor, and when used in combination with imatinib, it could reverse TKI-resistant CML [39]. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.